Medical treatment: does it influence the natural course of inflammatory bowel disease?

Abstract Background To investigate the incidence of very early onset inflammatory bowel disease (VEO-IBD) in a cohort representing two regions in Denmark during the period 2015–2019 and to assess the medical and surgical treatment. Methods All patients diagnosed with VEO-IBD within The Capital Region and The Zealand Region from January 1, 2015 to July 1, 2020 were included. Demographic and clinical data and medical and surgical treatment were extracted from the files. Results Forty patients with VEO-IBD were identified. The incidence rate was 2.0/100,000 (CI 95% 0.8–5.9) during the 2015–2019. Totally 35 patients (87.5%) received immunomodulatory therapy during follow-up. The cumulative risk of receiving immunomodulatory therapy after 1 year, 3 years and 5 years was 58% (95% CI 39–71), 88% (95% CI 70–95) and 91% (95% CI 73–97) respectively. Totally 23 patients (57.5%) received biological therapy. The cumulative risk of receiving biological therapy after 1 year, 3 years and 5 years was 37% (95% CI 19–50), 46% (95% CI 27–60) and 57% (95% CI 36–71) respectively. Six patients (15%) received vedolizumab. Four patients (10%) with VEO-IBD underwent a colectomy during the follow-up period of which two patients received vedolizumab. Conclusion The incidence of VEO-IBD was 2.0/100,000. Medical treatment with immunomodulators and biological therapy was used extensively, possibly reducing surgery. However, medical treatment remains a complicated balancing of the effect (anti-inflammatory), side effect (cancer risk) and surgery in VEO-IBD.

Download Full-text

Inflammatory bowel disease. Pathophysiology and medical treatment

Der Radiologe ◽

10.1007/s001170050316 ◽

1998 ◽

Vol 38 (1) ◽

pp. 3-7

Author(s):

C. von Ritter

Keyword(s):

Inflammatory Bowel Disease ◽

Medical Treatment ◽

Bowel Disease ◽

Inflammatory Bowel

Download Full-text

Faecal calprotectin: A reliable diagnostic and prognostic biomarker in inflammatory bowel disease

Bangladesh Journal of Medical Microbiology ◽

10.3329/bjmm.v8i1.31066 ◽

2017 ◽

Vol 8 (1) ◽

pp. 12-15

Author(s):

Ripon Barua ◽

Najmun Nahar ◽

Jogendra Nath Sarker ◽

Sultana Razia ◽

Abu Naser Ibne Sattar ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Medical Treatment ◽

Disease Control ◽

Bowel Disease ◽

Intestinal Inflammation ◽

Cross Sectional Study ◽

Faecal Calprotectin ◽

Cross Sectional ◽

Healthy Control ◽

Inflammatory Bowel

Faecal calprotectin (FC) is supposed to be a reliable biomarker that quantifies intestinal inflammation in inflammatory bowel disease (IBD). This cross sectional study was aimed to determine the role of FC level in screening of suspected IBD patients and monitoring treatment response. This study was conducted by measurement of FC using a commercially available ELISA kit among 50 patients with chronic diarrhea who underwent colonoscopic evaluation (25 IBD cases, 10 other organic bowel diseases and 15 disease control) and 12 healthy control. IBD patients were followed up after one month of medical treatment. FC level showed significantly higher value (p<0.001) among IBD patients (496.7±127.15?g/g) than those in disease control (82.17±75.64?g/g) and healthy control (27±18.2?g/g). Measurement of FC in diagnosing IBD revealed the sensitivity 100%, specificity 66%, PPV 83% and NPV 100%. The FC level decreased significantly (p<0.001) after one month of medical treatment of IBD patients (90±43?g/g) from pre treatment value (607.56±94?g/g). FC can be used as a reliable biomarker in screening of suspected IBD patients and to monitor treatment response.Bangladesh J Med Microbiol 2014; 08 (01): 12-15

Download Full-text